Mitochondrial antiviral signaling protein: a potential therapeutic target in renal disease

Front Immunol. 2023 Oct 12:14:1266461. doi: 10.3389/fimmu.2023.1266461. eCollection 2023.

Abstract

Mitochondrial antiviral signaling protein (MAVS) is a key innate immune adaptor on the outer mitochondrial membrane that acts as a switch in the immune signal transduction response to viral infections. Some studies have reported that MAVS mediates NF-κB and type I interferon signaling during viral infection and is also required for optimal NLRP3 inflammasome activity. Recent studies have reported that MAVS is involved in various cancers, systemic lupus erythematosus, kidney diseases, and cardiovascular diseases. Herein, we summarize the structure, activation, pathophysiological roles, and MAVS-based therapies for renal diseases. This review provides novel insights into MAVS's role and therapeutic potential in the pathogenesis of renal diseases.

Keywords: MAVS; NLRP3; inflammation; innate immune; renal disease.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunity, Innate
  • Kidney Diseases* / drug therapy
  • NF-kappa B / metabolism
  • Signal Transduction*

Substances

  • NF-kappa B

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by a grant from the National Natural Science Foundation of China (no. 82070760, 82070701), grants from the Nanjing National Commission on Health and Family Planning (no. ZKX19042), grant from the Nanjing Medical Key Science and Technology Development Project Fund (No. YKK19105), and grants from Academic Technology Programof Nanjing Medical University (No. NMUB20210073).